Iclusig 30MG tabs
Ended Awarded Last action
- Contract number
- 36C26024F0401
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI ENNFDLWFC6L1
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $173,716
Award facts
- Contract value 100% obligated
- $173,715.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Earth City, MO 63045, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$169 | |
| Original award | $173,885 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 20, awarded a delivery order contract to Takeda Pharmaceuticals America, Inc. for the supply of ICLUSIG 30mg tablets, valued at $173,715.75 under a firm fixed-price arrangement. The contract was awarded on May 10, 2024, with an ultimate completion date of May 9, 2025, and carries no small business set-aside designation. The pharmaceutical products will be delivered to a facility in Earth City, Missouri. This delivery order is placed against Takeda's existing GSA Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), as well as a $123.5 million Blanket Purchase Agreement with the VA National Acquisition Center specifically for ICLUSIG supply to VA medical facilities.
Takeda Pharmaceuticals America, Inc., a large foreign-owned subsidiary of Japan-based Takeda Pharmaceutical Company Limited, serves as a critical supplier of specialized oncology medications to VA healthcare systems. ICLUSIG (ponatinib) is a targeted cancer therapy used in the treatment of certain blood cancers, and this contract continues Takeda's established role as the primary federal supplier of this medication across multiple dosage strengths. The company's substantial federal contract portfolio, including a $2.9 billion Federal Supply Schedule contract running through September 2030, demonstrates its capacity to support VA medical facilities' pharmaceutical procurement needs through streamlined delivery order mechanisms.
Quick answers
Who was awarded contract 36C26024F0401?
36C26024F0401 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on May 10, 2024.
How much is contract 36C26024F0401 worth?
The government has obligated $173,716 on 36C26024F0401.
Is contract 36C26024F0401 an order under another contract?
Yes. 36C26024F0401 is a delivery order under 36F79718D0586, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26024F0401 competed?
The extent of competition for 36C26024F0401 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award